Merck HIV Pipeline Nears Key Inflection Point Ahead of ISLEND Data: RBC

RBC Capital Markets analysts said Merck (MRK) is approaching a key inflection point in its HIV pipeline, with upcoming clinical data for the ISLEND program and islatravir plus ulonivirine treatment.

Recommendation Change

The analysts did not change their current rating on Merck shares but noted that the upcoming data could be a positive catalyst. RBC's current price target for MRK is $135.

Analyst Rationale

The analysts believe that success of the ISLEND program (a long-acting integrase inhibitor) and the islatravir plus ulonivirine combination (a nucleoside RTI with a non-nucleoside RTI) could strengthen Merck's position in the growing HIV treatment market, especially as the market shifts toward long-acting therapies.

Context

These developments come amid increasing competition in the HIV treatment space from companies like Gilead Sciences (GILD) and ViiV Healthcare. Merck's stock has risen about 12% year-to-date.

What to Make of It

While the upcoming data presents a potential opportunity for Merck, investors should closely monitor clinical trial results, as any failure could negatively impact the stock.